Inovio Pharmaceuticals Inc (NASDAQ:INO) CEO Jong Joseph Kim sold 103,750 shares of the stock in a transaction dated Thursday, April 12th. The stock was sold at an average price of $5.14, for a total transaction of $533,275.00. Following the completion of the transaction, the chief executive officer now directly owns 2,395,557 shares of the company’s stock, valued at $12,313,162.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Shares of INO opened at $5.06 on Friday. The company has a market cap of $468.02, a P/E ratio of -4.64 and a beta of 2.51. Inovio Pharmaceuticals Inc has a twelve month low of $3.76 and a twelve month high of $9.86.
Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings results on Wednesday, March 14th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.30) by $0.06. The company had revenue of $8.80 million during the quarter, compared to the consensus estimate of $9.13 million. Inovio Pharmaceuticals had a negative net margin of 208.92% and a negative return on equity of 66.07%. The firm’s quarterly revenue was up 3.5% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.35) earnings per share. research analysts forecast that Inovio Pharmaceuticals Inc will post -1.07 EPS for the current fiscal year.
A number of equities analysts have weighed in on the stock. HC Wainwright set a $13.00 target price on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday. Maxim Group set a $8.00 target price on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday. Royal Bank of Canada raised their target price on shares of Inovio Pharmaceuticals from $11.00 to $14.00 and gave the company an “outperform” rating in a research note on Thursday, March 15th. BidaskClub raised shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, March 14th. Finally, ValuEngine downgraded shares of Inovio Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 1st. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and eight have assigned a buy rating to the stock. Inovio Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $19.07.
Several institutional investors and hedge funds have recently made changes to their positions in INO. Virginia Retirement Systems ET AL bought a new stake in shares of Inovio Pharmaceuticals during the third quarter valued at approximately $101,000. Neuberger Berman Group LLC bought a new stake in shares of Inovio Pharmaceuticals during the third quarter valued at approximately $115,000. Engineers Gate Manager LP bought a new stake in shares of Inovio Pharmaceuticals during the third quarter valued at approximately $117,000. Teacher Retirement System of Texas bought a new stake in shares of Inovio Pharmaceuticals during the fourth quarter valued at approximately $120,000. Finally, Belpointe Asset Management LLC bought a new stake in shares of Inovio Pharmaceuticals during the third quarter valued at approximately $150,000. 31.50% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: This article was first posted by Macon Daily and is the sole property of of Macon Daily. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://macondaily.com/2018/04/15/jong-joseph-kim-sells-103750-shares-of-inovio-pharmaceuticals-inc-ino-stock.html.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.